Hepatitis B Vaccine: New CDC Recommendations – Dec. 2025

Understanding the Shift in Hepatitis B Vaccination Guidance

For decades, the standard practice in the United States has been to administer the first dose of the hepatitis B vaccine to all newborns, regardless of their mother’s infection status. This universal vaccination policy, implemented in 1991, significantly reduced the incidence of hepatitis B infections in children. However, recent data and a review of evidence by the CDC’s Advisory Committee on Immunization Practices (ACIP) prompted a reassessment of this approach. The ACIP voted to recommend individual-based decision-making, a change the CDC formally adopted in December 2025.

This new guidance means that for infants whose mothers test negative for hepatitis B, the decision of whether to administer the vaccine at birth, or to defer it until the two-month well-child visit, is now a shared one between parents and their healthcare providers. If the birth dose is delayed, the CDC suggests initiating the vaccine series no earlier than two months of age. Crucially, infants born to mothers who test positive for hepatitis B, or whose status is unknown, will continue to receive the vaccine and Hepatitis B Immune Globulin (HBIG) within 12 hours of birth, as this remains the most effective way to prevent infection in these higher-risk cases. More details on this change are available from the CDC.

The Rationale Behind the Updated Recommendations

The ACIP’s decision to recommend individual-based decision-making was informed by several key factors. The committee noted the high reliability of prenatal hepatitis B screening, which effectively identifies nearly all infections during pregnancy. The incidence of perinatal hepatitis B transmission – the spread of the virus from mother to child during birth – is very low in the U.S. Due to existing prevention systems. The ACIP concluded that, in cases where a mother tests negative, families and healthcare providers should have the flexibility to determine the most appropriate timing for vaccination. This approach aims to balance the benefits of early vaccination with the desire to respect parental preferences and avoid unnecessary medical interventions when the risk of infection is minimal.

It’s significant to note that this change was not driven by concerns about vaccine safety. The hepatitis B vaccine remains a safe and effective tool for preventing serious liver disease, including cirrhosis and liver cancer. Rather, the shift reflects a move towards a more nuanced and individualized approach to vaccination, taking into account the specific risk profile of each infant. CNN provides additional context on the decision.

What Expecting Parents Need to Know

For expecting parents, understanding the new guidance is crucial. All pregnant women should continue to be tested for the hepatitis B virus as part of routine prenatal care. This testing is covered by all insurance programs. If a mother tests positive for hepatitis B, or her status is unknown, the infant will receive the hepatitis B vaccine and Hepatitis B Immune Globulin (HBIG) shortly after birth. This remains the standard of care to prevent infection in these cases.

However, if a mother tests negative, parents will now have a conversation with their healthcare provider about the timing of the hepatitis B vaccine series. They can choose to administer the vaccine at birth, or to delay it until the infant is at least two months old. This decision should be made collaboratively, taking into account the family’s individual circumstances and preferences. Factors to consider might include the presence of other household members with hepatitis B, or frequent contact with individuals from regions where hepatitis B is more common. The hepatitis B vaccine remains a safe and effective way to protect infants from this potentially serious infection.

Looking Ahead: CDC’s Next Steps

The CDC is taking several steps to implement these new recommendations. The agency will update its online resources, including the child and adolescent immunization schedule webpages, to reflect the shared clinical decision-making guidance for infants born to mothers who test negative for hepatitis B. They will also develop materials to support clinicians in having informed discussions with families about vaccination timing. The CDC will continue to monitor hepatitis B trends and vaccination coverage rates to assess the impact of these changes.

In addition to the change regarding the birth dose, the ACIP also recommended that clinicians and parents consider serology (antibody level) testing when evaluating the need for subsequent hepatitis B doses in children. The CDC will continue to review evidence related to this recommendation. Reuters reports on a decline in birth doses prior to the CDC’s decision, suggesting a pre-existing trend towards more individualized approaches.

Context: Recent Changes to the ACIP

The recent changes to hepatitis B vaccination recommendations are notable in the context of broader shifts within the CDC’s Advisory Committee on Immunization Practices (ACIP). In the summer of 2025, US Health and Human Services Secretary Robert F. Kennedy Jr. Removed all 17 previous members of the ACIP and appointed a new committee. This change in membership has led to a re-evaluation of several long-standing vaccination policies, with the hepatitis B recommendation being the most significant outcome to date.